{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:54:40Z","timestamp":1790790880716,"version":"4.1.0"},"reference-count":45,"publisher":"Informa UK Limited","issue":"7","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.2217\/imt-2016-0001","type":"journal-article","created":{"date-parts":[[2016,6,29]],"date-time":"2016-06-29T06:12:04Z","timestamp":1467180724000},"page":"809-819","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":45,"title":["Immune Checkpoint Blockade in Human Cancer Therapy: Lung Cancer and Hematologic Malignancies"],"prefix":"10.1080","volume":"8","author":[{"given":"Murali","family":"Janakiram","sequence":"first","affiliation":[{"name":"Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY10461, USA"},{"name":"Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY10461, USA"},{"name":"Microbiology & Immunology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY10461, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul","family":"Pareek","sequence":"additional","affiliation":[{"name":"Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY10461, USA"},{"name":"Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY10461, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiying","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY10461, USA"},{"name":"Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY10461, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa M","family":"Narasimhulu","sequence":"additional","affiliation":[{"name":"Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY10461, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingxing","family":"Zang","sequence":"additional","affiliation":[{"name":"Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY10461, USA"},{"name":"Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY10461, USA"},{"name":"Microbiology & Immunology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY10461, USA"},{"name":"Urology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY10461, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2016,6,28]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.22.012703.104803"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.03.030"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/334395a0"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa1348"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200694"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2736"},{"issue":"4","key":"e_1_3_2_10_1","first-page":"1111","article-title":"Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice","volume":"120","author":"Ramakrishnan R","year":"2010","unstructured":"Ramakrishnan R , AssudaniD, NagarajSet al. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J. Clin. Oncol.120(4), 1111\u20131124 (2010).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.4032"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1624"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-7-873"},{"issue":"15","key":"e_1_3_2_14_1","first-page":"8071","article-title":"Randomized Phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC)","volume":"27","author":"Zatloukal P","year":"2009","unstructured":"Zatloukal P , HeoDS, ParkKet al. Randomized Phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts27(15S), 8071 (2009).","journal-title":"ASCO Meeting Abstracts"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-0255"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.0970"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504627"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824"},{"issue":"15","key":"e_1_3_2_20_1","first-page":"3000","article-title":"A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors","volume":"31","author":"Herbst RS","year":"2013","unstructured":"Herbst RS , GordonMS, FineGDet al. A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. ASCO Meeting Abstracts31(Suppl. 15), 3000 (2013).","journal-title":"ASCO Meeting Abstracts"},{"key":"e_1_3_2_21_1","first-page":"8010","article-title":"Efficacy, safety and predictive biomarker results from a randomized Phase II study comparing MPDL3280A vs docetaxel in 2L\/3L NSCLC (POPLAR)","volume":"33","author":"Spira AI","year":"2015","unstructured":"Spira AI , ParkK, MazieresJet al. Efficacy, safety and predictive biomarker results from a randomized Phase II study comparing MPDL3280A vs docetaxel in 2L\/3L NSCLC (POPLAR). ASCO Meeting Abstracts33(Suppl. 15), 8010 (2015).","journal-title":"ASCO Meeting Abstracts"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(15)30072-1"},{"key":"e_1_3_2_23_1","first-page":"8030","article-title":"Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)","volume":"33","author":"Liu SV","year":"2015","unstructured":"Liu SV , PowderlyJD, CamidgeDRet al. Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts33(Suppl. 15), 8030 (2015).","journal-title":"ASCO Meeting Abstracts"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2015.02.007"},{"key":"e_1_3_2_25_1","first-page":"8032","article-title":"Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC)","volume":"33","author":"Rizvi NA","year":"2015","unstructured":"Rizvi NA , BrahmerJR, OuS-HIet al. Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts33(Suppl. 15), 8032 (2015).","journal-title":"ASCO Meeting Abstracts"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-567453"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.290.290"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0855"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2660"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1339"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4079"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70551-5"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2015.187"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.291.291"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.3685"},{"key":"e_1_3_2_37_1","volume-title":"57th American Society of Hematology SCI-8","author":"Bruce R","year":"2015","unstructured":"Bruce R , BlazarRSOC, MichaelC, Miloneet al. Role of PD-1\/PD-L1 in acute and chronic graft versus host disease. Presented at: 57th American Society of Hematology SCI-8FL, USA, 5\u20138December2015."},{"key":"e_1_3_2_38_1","volume-title":"57th ASH Annual Meeting and Exposition 2015.","author":"Reid W","year":"2015","unstructured":"Reid W , MerrymanHTK, Pier LuigiZinzaniet al. Safety and efficacy of allogeneic hematopoetic stem cell transplant (HSCT) after treatment with programmed cell death 1 (PD-1) inhibitors. Presented at: 57th ASH Annual Meeting and Exposition 2015.FL, USA, 5\u20138December2015 (Abstract 2018)."},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-168468"},{"key":"e_1_3_2_40_1","volume-title":"13th International Conference on Malignant Lymphoma.","author":"Philippe Armand JT","year":"2015","unstructured":"Philippe Armand JT , AlexanderLesokhin, AhmadHalwaniet al. Nivolumab in patients with relapsed or refractory lymphoid malignancies and classical hodgkin lymphoma: updated safety and efficacy results of a Phase 1 study (CA209\u2013039). Presented at: 13th International Conference on Malignant Lymphoma.Lugano, Switzerland. 17\u201320June2015 (Abstract 0100)."},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.355"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055818"},{"key":"e_1_3_2_43_1","volume-title":"UpToDate","author":"Postow M","year":"2016","unstructured":"Postow M , WolchokJ. Toxicities associated with checkpoint inhibitor immunotherapy. In: UpToDate, PostTW. (Ed), UpToDate, MA, USA.(2016)."},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.4358"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.11.016"},{"key":"e_1_3_2_46_1","first-page":"1","article-title":"The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases","volume":"8","author":"Saenger YM","year":"2008","unstructured":"Saenger YM , WolchokJD. The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases. Cancer Immun.8, 1 (2008).","journal-title":"Cancer Immun."}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/imt-2016-0001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:20:59Z","timestamp":1715991659000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/imt-2016-0001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.2217\/imt-2016-0001"],"URL":"https:\/\/doi.org\/10.2217\/imt-2016-0001","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"value":"1750-743X","type":"print"},{"value":"1750-7448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2016-01-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-06-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}